To validate this hypothesis, we subcutaneously implanted GL261 cells into WT and NFE2L1−/+ C57BL/6 mice and subsequently administered various treatments (Vehicle + IgG group, CD38 inhibitor group, Anti‐PD‐1 group, and CD38 inhibitor + Anti‐PD‐1 group) to evaluate their tumor‐inhibiting potential (Figure 7A). This evidence concerns the gene CD38 and neoplasm.